Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region

Nightingale Health Plc

Press release

27 January 2025 at 9:00 a.m. (EET)

Nightingale Health Plc ("Nightingale Health"), a pioneer in disease risk detection and preventative health, and Enigma Genomics ("Enigma") have signed a pilot agreement and a letter of intent to provide the Nightingale Remote Health Check to Enigma's customers in the Kingdom of Saudi Arabia and the MENA region.

Enigma, an innovative AI-powered genomics platform, is aiming to transform healthcare with advanced genetic analysis for diagnostic and research purposes. Providing direct-to-consumer and clinical genetic sequencing, Enigma empowers individuals and medical professionals to make informed decisions focused on disease prevention and health optimization. Aiming to lead precision medicine in Saudi Arabia and the Middle East, Enigma is expanding its test offerings by utilizing the latest technologies to enhance preventative healthcare, which has enabled Enigma to launch the region's first large-scale whole genome sequencing-based genetic screening program, enabling individuals to make informed healthcare decisions for better health and well-being.

The letter of intent contains four phases for the collaboration: pilot, service launch, expansion of sales and full-scale commercial adoption. The companies will start preparations for the pilot in early 2025 and the aim is to transition phase by phase to a continued commercial service model making the Nightingale Remote Health Check widely available for Enigma's customers. The Nightingale Remote Health Check provides disease risk assessment for multiple chronic diseases utilising just a single blood sample without the need to collect clinical parameters such as BMI, family history or blood pressure. In addition, Nightingale Remote Health Check accurately measures dozens of biomarkers from a single blood sample collected at-home, including cholesterols, apolipoproteins and fatty acids like omega-3. Many of these blood biomarkers have established clinical relationships to disease and can help guide important lifestyle interventions - such as diet and exercise. 

"We share the vision of helping individuals and health systems to identify health risks and prevent diseases, and combining our disease risk assessment to Enigma's genetics products provides more comprehensive health assessment and insights into what kind of preventative actions are most impactful" says Teemu Suna, CEO and Founder of Nightingale Health. "We are excited about the opportunity to bring Nightingale Health's technology into a new region, where we strongly believe we can contribute to building the preventative health system" he continues.

"At Enigma Genomics, we're driven by a vision to transform healthcare through innovation and personalized solutions. Partnering with Nightingale Health is an exciting step forward in this journey. By integrating their cutting-edge Remote Health Check into our offerings, we're giving individuals across the MENA region the tools to understand their health risks and take proactive steps toward prevention. This collaboration is more than just technology-it's about empowering people to lead healthier, more informed lives," said Eng. Musaad AlDubayan, Managing Director of Enigma Genomics.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

About Nightingale Health

Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world's most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale's Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com/

About Enigma Genomics

Enigma Genomics is an integrated molecular, clinical, and computational genomics platform dedicated to decoding the complexities of the human genome to deliver actionable insights for patients, researchers, and healthcare providers. By combining state-of-the-art sequencing technologies with innovative AI-driven systems, Enigma Genomics is revolutionizing the way we understand, interpret, and apply genetic information. The company's mission is to empower individuals and medical professionals with precise, personalized genomic data, enabling informed decisions that transform health and life outcomes while accelerating the development of targeted therapies. Leveraging these advances, Enigma Genomics has designed and executed state-of-the-art programs for government and private healthcare systems, driving innovation and improving health outcomes on a larger scale.

For inquiries:

Info@enigmagenomics.com
https://enigmagenomics.com/web/